PL341795A1 - Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds - Google Patents

Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds

Info

Publication number
PL341795A1
PL341795A1 PL98341795A PL34179598A PL341795A1 PL 341795 A1 PL341795 A1 PL 341795A1 PL 98341795 A PL98341795 A PL 98341795A PL 34179598 A PL34179598 A PL 34179598A PL 341795 A1 PL341795 A1 PL 341795A1
Authority
PL
Poland
Prior art keywords
compounds
obtaining
compositions containing
bicycle
pharmacological compositions
Prior art date
Application number
PL98341795A
Other languages
English (en)
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Ashok Channaveerappa Bajji
Shivaramayya Kalchar
Rajagopalan Ramanujam
Ranjan Chakrabarti
Original Assignee
Reddy Research Foundation
Reddy Cheminor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/085,292 external-priority patent/US6265401B1/en
Application filed by Reddy Research Foundation, Reddy Cheminor filed Critical Reddy Research Foundation
Publication of PL341795A1 publication Critical patent/PL341795A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL98341795A 1998-05-27 1998-10-26 Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds PL341795A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/085,292 US6265401B1 (en) 1997-10-27 1998-05-27 Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
PCT/US1998/022570 WO1999020614A1 (en) 1998-05-27 1998-10-26 Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
PL341795A1 true PL341795A1 (en) 2001-05-07

Family

ID=22190649

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98341795A PL341795A1 (en) 1998-05-27 1998-10-26 Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds

Country Status (6)

Country Link
EP (1) EP1082313A1 (zh)
JP (1) JP2002507543A (zh)
CN (1) CN100357281C (zh)
NZ (1) NZ504106A (zh)
PL (1) PL341795A1 (zh)
WO (1) WO1999020614A1 (zh)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2355645A1 (en) * 1998-12-17 2000-06-22 Mindset Biopharmaceuticals (Usa), Inc. Increasing brain glucose utilization
WO2000063189A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
EP1171430A1 (en) * 1999-04-16 2002-01-16 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
US6528507B1 (en) 1999-04-16 2003-03-04 Dr. Reddy's Laboratories Limited Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
AU3958000A (en) * 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
EP1171438A1 (en) * 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
JP2002542237A (ja) * 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
IL146104A0 (en) 1999-04-28 2002-07-25 Reddy Research Foundation Substituted bicyclic heterocyclic compounds, processes for their preparation and pharmaceutical compositions containing the same
NZ520402A (en) * 2000-01-19 2006-04-28 Cadila Healthcare Ltd Novel compounds having hypolipedemic, hypocholesteremic activites, process for their preparation and pharmaceutical compositions containing them
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
KR20020070508A (ko) * 2000-01-28 2002-09-09 노보 노르디스크 에이/에스 프로피온산 유도체 및 당뇨병 및 비만의 치료에 그것의 사용
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
AU2001261503A1 (en) * 2000-05-12 2001-11-26 Ortho-Mcneil Pharmaceutical, Inc. Methods of treatment using benzoxazinones as peroxisome proliferator activated receptor gamma modulators
US6908908B2 (en) 2000-05-12 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4] oxazin-3-ones
WO2001087862A2 (en) * 2000-05-12 2001-11-22 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4h-benzo[1,4]oxazin-3-ones
EP1280782A2 (en) * 2000-05-12 2003-02-05 Ortho-McNeil Pharmaceutical, Inc. Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
WO2002020499A1 (en) * 2000-09-04 2002-03-14 Dr. Reddy's Research Foundation Process for the preparation of 2-[3,4-dihydro-1,4-benzothiazin-4-yl]ethylmethane sulphonate
WO2002030914A1 (en) * 2000-10-12 2002-04-18 Dr. Reddy's Research Foundation Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
WO2002100397A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
WO2003006022A1 (en) * 2001-07-09 2003-01-23 Dr. Reddy's Laboratories Ltd. Tetrahydroquinoline derivatives and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
PL369655A1 (en) * 2001-10-16 2005-05-02 Dr.Reddy's Laboratories Ltd. Novel-beta-phenyl-alpha-oxysubstituted propionic derivatives, process for its preparation and their use in the preparation of pharmaceutically important compounds
JP2005518408A (ja) 2001-12-29 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用
WO2003099800A1 (en) * 2002-05-23 2003-12-04 Dr. Reddy's Laboratories Limited An improved process for the preparation of bicyclic antidiabetic agents
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MY191100A (en) 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014174524A1 (en) 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (zh) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
JP6840853B2 (ja) 2016-12-09 2021-03-10 カディラ・ヘルスケア・リミテッド 原発性胆汁性胆管炎の治療
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110092774B (zh) * 2018-01-29 2022-04-08 中国科学院上海药物研究所 芳香丙酸类衍生物、及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173350B1 (da) * 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
US5496815A (en) * 1990-02-08 1996-03-05 Tanabe Seiyaku Co., Ltd. Thiazine (or oxazine) derivatives and preparation thereof
CA2035147A1 (en) * 1990-02-08 1991-08-09 Kousuke Yasuda Thiazine (or oxazine) derivatives and preparation thereof
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
JPH05194236A (ja) * 1991-07-25 1993-08-03 Tanabe Seiyaku Co Ltd 中枢性カルシウム拮抗剤
WO1996004261A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
JPH0912575A (ja) * 1995-06-28 1997-01-14 Sankyo Co Ltd ベンゾオキサジンおよびベンゾチアジン誘導体

Also Published As

Publication number Publication date
WO1999020614A1 (en) 1999-04-29
EP1082313A1 (en) 2001-03-14
CN1281443A (zh) 2001-01-24
CN100357281C (zh) 2007-12-26
NZ504106A (en) 2003-02-28
JP2002507543A (ja) 2002-03-12

Similar Documents

Publication Publication Date Title
PL341795A1 (en) Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds
GB9815166D0 (en) Compounds for mass spectrometry
PL341984A1 (en) Novel tricycle compounds
GB0106312D0 (en) Process
GB9816385D0 (en) Process
TW360184U (en) Improved structure for bicycle
PL341549A1 (en) Novel-beta-carbolinic compounds, method of obtaining them and pharmacological compositions containing such compounds
HUP0003273A3 (en) Process for producing isoxazolidinedione compounds
GB9820195D0 (en) Process
GB9825424D0 (en) Process
PL342098A1 (en) Pharmacological compositions for treating diskineses
AU138774S (en) Distiller
GB9816564D0 (en) Process
GB9806527D0 (en) Process
GB2340237B (en) Compounds for mass spectrometry
GB2335866B (en) Process
GB9820914D0 (en) Process
TW382363U (en) Structure improvement for electrical-booster bicycle
TW356807U (en) Improved structure for tricycle
TW397003U (en) Lock for motorcycle
HU9802686D0 (en) Process for guaranteed hair-restoration
TW377680U (en) Structure improvement for motorcycle lock
GB9807934D0 (en) Process for phosphodiesterase
GB9817171D0 (en) Process for making 1,5-distributed imidazoles
GB9805196D0 (en) Process

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)